Answers are grounded in this paper and cite their sources.
Significance Statement Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels are potential modifiable risk factors to prevent cardiovascular disease in CKD. Studies evaluating intestinal phosphate binders found modest efficacy for lowering phosphate and FGF23 levels during short-term follow-up in CKD. In their randomized, placebo-controlled trial in 205 participants with stage 3b/4 CKD, the authors evaluated the effects of nicotinamide (an inhibitor of active intestinal phosphate transport), the phosphate binder lanthanum carbonate, or both, versus placebo over 12 months. They found that neither drug, alone or together, reduced serum phosphate or FGF23. Participants taking lanthanum carbonate had reductions in urinary phosphate, however gastrointestinal symptoms limited adherence. Secondary on-treatment analyses suggest that blocking intestinal phosphate absorption may lower FGF23, suggesting potential opportunities for future studies using novel therapies with better tolerability. Background Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported modest efficacy in phosphate and FGF23 reduction with intestinal phosphate binders in CKD. Methods To investigate effects of lanthanum carbonate (LC; a phosphate binder) and/or nicotinamide (NAM; an inhibitor of active intestinal phosphate transport) on serum phosphate and FGF23 in stage 3b/4 CKD, we conducted a randomized trial among individuals with eGFR 20–45 ml/min per 1.73 m 2 to NAM (750 mg twice daily) plus LC (1000 mg thrice daily), NAM plus LC placebo, LC plus NAM placebo, or double placebo for 12 months. Dual primary end points were change from baseline in serum phosphate and intact FGF23 concentrations. Results Mean eGFR for the 205 participants was 32ml/min per 1.73 m 2 . At baseline, serum phosphate was 3.7 mg/dl and median FGF23 was 99 pg/ml (10th, 90th percentiles: 59, 205). Mean rates of change in phosphate increased slightly over 12 months in all groups and did not differ significantly across arms. Similarly, percent changes in FGF23 per 12 months increased for all arms except LC plus placebo, and did not differ significantly across arms. Gastrointestinal symptoms limited adherence. Adverse events rates were similar across arms. Conclusions LC and/or NAM treatment did not significantly lower serum phosphate or FGF23 in stage 3b/4 CKD over 12 months. Although these agents appeared safe, intestinal symptoms limited adherence. Reducing phosphate and FGF23 in nondialysis CKD will require new approaches.
No takes yet. Share an insight, caveat, or question.
Ix et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: